Case 1:20-cv-01644-RGA Document 1-47 Filed 12/03/20 Page 1 of 4 PageID #: 1271
`Case 1:20-cv-01644-RGA Document 1-47 Filed 12/03/20 Page 1 of 4 PageID #: 1271
`
`
`
`
`
`EXHIBIT 47
`
`
`
`
`
`EXHIBIT 47
`
`
`
`
`
`
`

`

`11/17/2020
`
`Press Release
`Case 1:20-cv-01644-RGA Document 1-47 Filed 12/03/20 Page 2 of 4 PageID #: 1272
`
`RECENT ARTICLES
`
`Select an area of interest
`
`The New Workflow:
`How Labs Will Benefit
`from TSO 500 Updates
`
`Accelerating Genomics:
`Astarte Medical
`Launches NICUtrition®
`
`Illumina Pledges US
`$20 Million in
`Sequencing Tech for
`Africa
`
`SHARE
`
`  
`
`News Center / Press Releases:
`
`PRESS RELEASE
`
`Illumina Launches TruSight
`Tumor 170
`
`Newest Addition in Clinical Cancer Research Portfolio Aims to Establish a
`Standardized Method for Tumor Profiling
`
`SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2016-- Illumina, Inc. (NASDAQ:ILMN) today
`announced the launch of TruSight® Tumor 170, a 170 gene next-generation
`sequencing solution to support the transformation of the tumor-profiling paradigm
`from a series of single-gene tests to a multi-analyte approach, providing a more
`thorough picture of a tumor’s genomic landscape.
`
`TruSight Tumor 170 offers an integrated DNA and RNA enrichment-based workflow,
`targeting cancer-related genetic aberrations, including small variants, gene
`amplifications, gene fusions, and splice variants. With optimized bioinformatics tools
`and automation options, laboratories can implement the assay on an in-house,
`research use only NextSeq® instrument. Designed to support limited nucleic acid
`input from formalin-fixed, paraffin-embedded (FFPE) samples, TruSight Tumor 170
`facilitates efficient evaluation of biomarkers.
`
`“Having broader gene content allows us to improve cancer research by assessing
`more genes and to identify structural alterations that are important targets for
`developing therapies,” said pathologist Anthony Magliocco. “We hope these
`capabilities will improve clinical cancer research by streamlining the testing of solid
`tumors. Due to the flexibility of the enrichment methodology upon which TruSight
`Tumor 170 is based, this technology has the potential to serve as a platform for many
`applications beyond solid tumor profiling.”
`
`“This new assay is poised to help realize the potential of precision oncology,” said
`John Leite, PhD, Vice President of Oncology at Illumina. “By integrating DNA and RNA
`into one protocol, clinical researchers are able to accelerate comprehensive analysis
`of cancer-related variants and maximize the data obtainable from precious
`specimens. Looking forward, we aim to deploy the underlying assay method at the
`heart of TruSight Tumor 170 as a universal standard for optimized tissue assessment
`across a variety of applications with both fixed and customizable panels.”
`
`“We’re committed to delivering the tools that enable a shared vision of personalized
`oncology,” said Francis deSouza, President and CEO of Illumina. “We believe the
`introduction of TruSight Tumor 170 will enable research insights that will positively
`impact cancer patients in the future.”
`
`TruSight Tumor 170 offers broader investigational power:
`
`Enrichment-based assay that evaluates DNA and RNA in one integrated
`protocol
`170 unique genes informed by partnering pharmaceutical companies, academic
`community leaders, and industry guidance
`
`https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e7bbfe59-14cd-4c23-b45c-027a3cba34c5
`
`1/3
`
`

`

`11/17/2020
`
`Press Release
`Case 1:20-cv-01644-RGA Document 1-47 Filed 12/03/20 Page 3 of 4 PageID #: 1273
`
`Integrated workflow requires only 40ng of DNA and RNA from FFPE samples,
`allowing more comprehensive testing while preserving precious samples
`Underlying assay method to serve as a standard for optimized tissue
`assessment across a variety of applications
`
`TruSight Tumor 170 will begin shipping in Q1 2017. For more information, please visit
`www.illumina.com/TruSightTumor170.
`
`For Research Use Only. Not for use in diagnostic procedures.
`
`About Illumina
`
`Illumina is improving human health by unlocking the power of the genome. Our focus
`on innovation has established us as the global leader in DNA sequencing and array-
`based technologies, serving customers in the research, clinical, and applied
`markets. Our products are used for applications in the life sciences, oncology,
`reproductive health, agriculture, and other emerging segments. To learn more, visit
`www.illumina.com and follow @illumina.
`
`Use of forward-looking statements
`
`This release contains projections, information about our financial outlook, earnings
`guidance, and other forward-looking statements that involve risks and uncertainties.
`These forward-looking statements are based on our expectations as of the date of
`this release and may differ materially from actual future events or results. Among the
`important factors that could cause actual results to differ materially from those in any
`forward-looking statements are (i) our ability to further develop and commercialize
`our instruments and consumables and to deploy new products, services and
`applications, and expand the markets for our technology platforms; (ii) our ability to
`manufacture robust instrumentation and consumables; (iii) our ability to successfully
`identify and integrate acquired technologies, products or businesses; (iv) the future
`conduct and growth of the business and the markets in which we operate; (v)
`challenges inherent in developing, manufacturing, and launching new products and
`services; and (vi) the application of generally accepted accounting principles, which
`are highly complex and involve many subjective assumptions, estimates, and
`judgments, together with other factors detailed in our filings with the Securities and
`Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or
`in information disclosed in public conference calls, the date and time of which are
`released beforehand. We undertake no obligation, and do not intend, to update these
`forward-looking statements, to review or confirm analysts’ expectations, or to
`provide interim reports or updates on the progress of the current quarter.
`
`View source version on businesswire.com:
`http://www.businesswire.com/news/home/20161107005280/en/
`
`Source: Illumina, Inc.
`
`Illumina, Inc.
`Investors:
`Rebecca Chambers, 858-255-5243
`IR@illumina.com
`or
`Media:
`Jen Carroll, 858-882-6822
`PR@illumina.com
`
`https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e7bbfe59-14cd-4c23-b45c-027a3cba34c5
`
`2/3
`
`

`

`11/17/2020
`
`Press Release
`Case 1:20-cv-01644-RGA Document 1-47 Filed 12/03/20 Page 4 of 4 PageID #: 1274
`
`Innovative technologies
`
`At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making
`studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver
`innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places
`high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we
`strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking
`advancements in life science research, translational and consumer genomics, and molecular diagnostics.
`For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
`
`© 2020 Illumina, Inc. All rights reserved.
`
`All trademarks are the property of Illumina, Inc. or their respective owners.
`For specific trademark information, see www.illumina.com/company/legal.html.
`
`Privacy Policy
`
`
`
`
`
`
`
`
`
`https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=e7bbfe59-14cd-4c23-b45c-027a3cba34c5
`
`3/3
`
`